RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Any comments on this from Leede's Doug Loe?Concur with
scarlet1967. "I am not trying to be optimistic but realistic. Fact is a very small portion of docetaxel enter the cells, the point Juniper was making"
The whole point of SORT+ technology is how concentrated docetaxel could be delivered to the cell. The MTD could be 1.5x or 3x as long as docetaxel could be internalized into cancerous cells multiple times the existing chemo process with docetaxel alone. Now they haven’t shared the PK/PD data so we don’t know but they do or at least based on what they have seen so far they have some sort of idea how the drug behaved and based on that they will be using a “good” dose.
Now how can one interpret “good”? Is it necessarily a large dose? Is it because a good portion of the PDC has internalized? Is it because it bypassed the MDR1? Agree. "Whatever that “good” dose means it didn’t stop the trial on the contrary they are allocating more resources to expand the phase1b to more cancers. Why would they add to the costs if they didn’t believe in the potentials? That’s all we know for now and I don’t see it as a negative thing but of course this is an ongoing process and it can hit the brick wall anytime. But JFM should stop all the speculating because he is “in the dark”."
Well, the whole JFM's argument is the low MTD of 1.5x standard docetaxel. He ignored the cancerous cell internalizing mechanism of TH1902. Like a hunter, he could shoot a bird with a bazooka or with a sniping riffle.